Evotec SE — Regulatory Filings 2012

Apr 26, 2012

News Details

Corporate | 26 April 2012 07:28

Evotec and Active Biotech Extend and Expand Medicinal Chemistry Collaboration

Evotec AG / Key word(s): Alliance

26.04.2012 / 07:28

---

Hamburg, Germany - 26 April 2012: Evotec AG (Frankfurt Stock
Exchange: EVT, TecDAX) today announced that it has extended and expanded
its medicinal chemistry collaboration with Active Biotech AB (NASDAQ OMX:
ACTI), to further advance an existing programme, which has entered the lead
optimisation phase. The programme aims to find novel small molecule
modulators of a priority biological target, selected by Active Biotech,
involved in immune disorders and cancer.

The programme was initiated in 2010 with a high throughput screen followed
by extensive hit validation and hit-to-lead activities, leveraging Evotec's
hit identification and integrated medicinal chemistry platforms.

Dr Mario Polywka, Chief Operating Officer at Evotec stated: 'We
are delighted that our already successful collaboration with Active Biotech
has been extended and expanded with the aim of taking this exciting
programme through lead optimisation towards candidate nomination. This is
an area where Evotec has a significant track record of success and we look
forward to leveraging our expertise to assist Active Biotech in finding
novel treatments addressing cancer and autoimmune disorders.'

Dorthe da Graça Thrige, Director of Development of Active
Biotech, commented: 'Active Biotech strives to develop, efficiently
and cost-effectively, new remedies for illnesses where today's
treatment options are inadequate, especially in the area of cancer and
autoimmune diseases. It is key for us to collaborate with first class
companies and we have been very impressed with Evotec's hit
identification and subsequent hit to lead activities on this important
target and now look forward to progressing the leads through to candidate
drug selection.'

No financial details are disclosed.

Contact Evotec AG:
Dr Werner Lanthaler
Chief Executive Officer
Phone: +49.(0)40.56081-242
werner.lanthaler@evotec.com

FORWARD LOOKING STATEMENTS
Information set forth in this press
release contains forward-looking statements, which involve a number of
risks
and uncertainties. The forward-looking statements contained herein
represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of
risks and uncertainties, many of which are beyond our control, and which
could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.

End of Corporate News

---

26.04.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart

End of News DGAP News-Service

166697 26.04.2012